OGT to exhibit its tailored biomarker discovery solutions at Companion Diagnostics 2011

Oxford, UK – 22^nd March 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be attending this year’s Companion Diagnostics Summit Europe in Frankfurt (22^nd to 24^th March). Will Colón (Business Development Director, Biomarker Discovery) and Graham Speight (Head of Genomic Biomarkers) will be present to talk with delegates about OGT’s tailored biomarker discovery solutions. The aim of the meeting is to discuss the best way to convert biomarker research into more accurate diagnostic methods and safer and more successful drug treatment strategies. OGT has already had significant success developing reliable and accurate solutions as part of its in-house biomarker discovery programmes, targeting diseases such as prostate cancer, systemic lupus erythematosus (SLE) and colorectal cancer.

 

Visit the OGT booth to meet the team and discuss how OGT’s DNA, RNA and protein biomarker technologies could help optimise your drug discovery and diagnostic development programmes, or for more information visit www.ogt.co.uk/diagnosticbiomarkers .

 

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk

W: www.ogt.co.uk

 

About Oxford Gene Technology

 

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

 

Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.

 

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

 

CytoSure™: For research use only

This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.